Sven Akkerman

762 total citations
9 papers, 617 citations indexed

About

Sven Akkerman is a scholar working on Molecular Biology, Social Psychology and Pharmacology. According to data from OpenAlex, Sven Akkerman has authored 9 papers receiving a total of 617 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 5 papers in Social Psychology and 4 papers in Pharmacology. Recurrent topics in Sven Akkerman's work include Phosphodiesterase function and regulation (6 papers), Neuroendocrine regulation and behavior (5 papers) and Cholinesterase and Neurodegenerative Diseases (4 papers). Sven Akkerman is often cited by papers focused on Phosphodiesterase function and regulation (6 papers), Neuroendocrine regulation and behavior (5 papers) and Cholinesterase and Neurodegenerative Diseases (4 papers). Sven Akkerman collaborates with scholars based in Netherlands, United States and Germany. Sven Akkerman's co-authors include Jos Prickaerts, Arjan Blokland, Harry W.M. Steinbusch, Nick P. van Goethem, Kris Rutten, C.K. Lieben, Hieronymus J.M. Gijselaers, Eva Bollen, Tim Vanmierlo and Jochen De Vry and has published in prestigious journals such as PLoS ONE, Psychopharmacology and European Journal of Pharmacology.

In The Last Decade

Sven Akkerman

9 papers receiving 601 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sven Akkerman Netherlands 9 293 183 179 149 87 9 617
Nick P. van Goethem Netherlands 13 371 1.3× 247 1.3× 169 0.9× 174 1.2× 73 0.8× 22 709
Katalin Szebeni United States 16 188 0.6× 300 1.6× 120 0.7× 120 0.8× 169 1.9× 24 798
Lilian Canetti Canada 8 314 1.1× 206 1.1× 95 0.5× 73 0.5× 146 1.7× 8 745
Eva Bollen Netherlands 12 589 2.0× 226 1.2× 358 2.0× 100 0.7× 54 0.6× 14 884
Andréa da Silva Torrão Brazil 18 236 0.8× 272 1.5× 206 1.2× 114 0.8× 62 0.7× 40 838
Anita J. Bechtholt United States 17 335 1.1× 562 3.1× 108 0.6× 125 0.8× 121 1.4× 20 869
Jane Gartlon United Kingdom 13 243 0.8× 306 1.7× 101 0.6× 128 0.9× 30 0.3× 18 628
Tobias Halene United States 14 431 1.5× 364 2.0× 94 0.5× 270 1.8× 42 0.5× 21 908
Christelle Repérant France 17 311 1.1× 479 2.6× 126 0.7× 101 0.7× 135 1.6× 20 842
Reesha R. Patel United States 16 186 0.6× 284 1.6× 70 0.4× 112 0.8× 159 1.8× 24 655

Countries citing papers authored by Sven Akkerman

Since Specialization
Citations

This map shows the geographic impact of Sven Akkerman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sven Akkerman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sven Akkerman more than expected).

Fields of papers citing papers by Sven Akkerman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sven Akkerman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sven Akkerman. The network helps show where Sven Akkerman may publish in the future.

Co-authorship network of co-authors of Sven Akkerman

This figure shows the co-authorship network connecting the top 25 collaborators of Sven Akkerman. A scholar is included among the top collaborators of Sven Akkerman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sven Akkerman. Sven Akkerman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Snyder, Gretchen L., Jos Prickaerts, Lei Zhang, et al.. (2016). Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats. Psychopharmacology. 233(17). 3113–3124. 49 indexed citations
2.
Vanmierlo, Tim, Sven Akkerman, Marlies van Duinen, et al.. (2016). The PDE4 inhibitor roflumilast improves memory in rodents at non-emetic doses. Behavioural Brain Research. 303. 26–33. 93 indexed citations
3.
Akkerman, Sven, Arjan Blokland, & Jos Prickaerts. (2015). Possible overlapping time frames of acquisition and consolidation phases in object memory processes: a pharmacological approach. Learning & Memory. 23(1). 29–37. 19 indexed citations
5.
Rutten, Kris, Sven Akkerman, Arjan Blokland, et al.. (2012). Phosphodiesterase type 5 (PDE5) inhibition improves object recognition memory: Indications for central and peripheral mechanisms. Neurobiology of Learning and Memory. 97(4). 370–379. 53 indexed citations
6.
Goethem, Nick P. van, Kris Rutten, F. Josef van der Staay, et al.. (2012). Object recognition testing: Rodent species, strains, housing conditions, and estrous cycle. Behavioural Brain Research. 232(2). 323–334. 92 indexed citations
7.
Akkerman, Sven, Arjan Blokland, Nick P. van Goethem, et al.. (2012). Object recognition testing: Methodological considerations on exploration and discrimination measures. Behavioural Brain Research. 232(2). 335–347. 159 indexed citations
8.
Akkerman, Sven, Jos Prickaerts, Harry W.M. Steinbusch, & Arjan Blokland. (2012). Object recognition testing: Statistical considerations. Behavioural Brain Research. 232(2). 317–322. 94 indexed citations
9.
Donkelaar, Eva L. van, Kris Rutten, Arjan Blokland, et al.. (2008). Phosphodiesterase 2 and 5 inhibition attenuates the object memory deficit induced by acute tryptophan depletion. European Journal of Pharmacology. 600(1-3). 98–104. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026